Home / Publications / Pain Research Forum / Papers of the Week / Efficacy and safety of seltorexant as adjunctive therapy in major depressive disorder: A phase 2b, randomized, placebo-controlled, adaptive dose-finding study.
Efficacy and safety of seltorexant as adjunctive therapy in major depressive disorder: A phase 2b, randomized, placebo-controlled, adaptive dose-finding study.
Seltorexant, a selective antagonist of human orexin-2 receptors, demonstrated antidepressant effects in a previous exploratory study in patients with major depressive disorder (MDD).
